No benefit from adjuvant sunitinib, sorafenib in locally advanced renal cell carcinoma
the ONA take:
According to initial results presented this week at the 2015 Genitourinary Cancers Symposium in Orlando, Florida, the use of either Nexavar (sorafenib) or Sutent (sunitinib) provide no benefit to patients with locally advanced renal cell carcinoma who are at a high risk of recurrence.
The phase 3 trial conducted by the ECOG-ACRIN Cancer Research Group is the first and largest study reporting on the efficacy of sunitinib or sorafenib in patients who have undergone surgery to remove the kidney tumor.
"Unfortunately we found that the use of sunitinib or sorafenib in this setting did not reduce the incidence of recurrence as compared to standard care," said lead researcher Naomi B. Haas, MD, from the University of Pennsylvania's Abramson Cancer Center in Philadelphia.
For the international, phase III study, researchers enrolled 1,943 patients considered at high risk for recurrence following surgery to remove a kidney tumor and randomly assigned them to receive sorafenib, sunitinib, or placebo for 1 year.
Results of the study showed a median progression-free survival of 5.6 years for those treated with sunitinib compared with 5.6 years for those treated with sorafenib and 5.7 years for those who received placebo.
Use of either Nexavar (sorafenib) or Sutent (sunitinib) provide no benefit to patients with locally advanced renal cell carcinoma.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
- Urine Drug Testing Policy Can Assist Opioid Treatment Decisions
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|